Our look is new. Our purpose is the same. Learn more about our brand evolution.
In our webinar from May 22, Samantha LoRusso, MD, provides a concise introduction to the basic facts about FSH muscular dystrophy and answers dozens of questions from our live webinar […]
[…] in Baltimore, Maryland, answers some commonly asked questions. Q. What is the genetic cause of FSHD? Let me begin by saying that the genetics of FSHD is quite complex! There […]
[…] quality of life By Yi-Wen Chen, PhD and Jean Mah, MD While most people with FSHD develop muscle weakness during late teen years or adulthood, about 4 percent of patients […]
From Fulcrum Therapeutics press release. Fulcrum plans to launch a Phase 2b clinical trial in FSHD in mid-2019 CAMBRIDGE, Mass., April 23, 2019 – Fulcrum Therapeutics, a biotechnology company focused […]
The FSHD Society today announced that Jamshid Arjomand, PhD, has joined the organization as its Chief Science Officer. The Society is the world’s largest research-focused patient advocacy organization for facioscapulohumeral […]
